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0.9 6 0.56, 4.2 6 0.79 and 4.9 6 0.84 in the calcium, oral, andComparison of treatments for mild secondary hyperparathyroid-
IV groups, respectively (P , 0.01).ism in hemodialysis patients.
Conclusion. In mild secondary hyperparathyroidism, all threeBackground. In the management of patients with mild sec-
strategies are effective. High-dose CaCO3 alone may be suffi-ondary hyperparathyroidism, it is not known whether calcium
cient to control PTH with a favorable side-effect profile, butsupplementation alone is sufficient to correct abnormalities in
calcitriol appears to have additional suppressive effects on bonebone and mineral metabolism or if calcitriol is needed in either
that are greater following the intravenous route of administra-physiologic oral or intravenous pharmacologic doses.
tion and may increase the risk of adynamic bone disease.Methods. This was a 40-week prospective nonmasked trial
of 52 patients [parathyroid hormone (PTH) 150 to 600 pg/mL]
who were randomized to receive escalating doses of either
calcium carbonate (CaCO3) alone (calcium group, N 5 11), Secondary hyperparathyroidism (HPT) is prevalent indaily oral calcitriol (oral group, N 5 20), or intermittent intrave-
patients with end-stage renal disease (ESRD). Up tonous calcitriol (IV group, N 5 21). The groups were compared
with regard to changes in serum intact PTH, serum bone- 75% of hemodialysis patients will have elevated parathy-
specific alkaline phosphatase (BAP), incidence of hypercalce- roid hormone (PTH) levels, consistent with secondary
mia (.10.5 mg/dL), and hyperphosphatemia (.6.5 mg/dL). HPT, and 40 to 50% of patients initiating hemodialysisResults. PTH levels decreased in all groups (P , 0.01, paired
will have PTH levels that are indicative of mild secondaryt-test). In the calcium group, PTH (mean 6 sem) decreased
HPT (150 to 600 pg/mL) [1]. Because of end-organ resis-from 325 6 46.2 to 160 6 44.5 pg/mL. In the oral group, it
decreased from 265 6 26.4 to 125 6 23.7 pg/mL, and in the tance to PTH in uremia [2], some degree of hyperpara-
IV group, it decreased from 240 6 27.7 to 65 6 10.0 pg/mL. thyroidism is needed to maintain normal bone metabo-
Upon analysis of covariance, controlling for the initial PTH
lism in patients with ESRD. Indeed, using this standardlevel, we found no differences in the PTH response between
assay for intact PTH, the optimal levels of intact PTHthe groups (P . 0.10). In contrast, the BAP concentration
increased from 20.7 6 7.6 to 27.5 6 7.0 mg/L in the calcium associated with normal bone histology are between 1.5
group (P 5 0.17), decreased from 20.6 6 3.9 to 17.8 6 4.5 and 2.5 times the upper reference limit of normal subjects
mg/L in the oral group (P 5 0.26), and from 19.1 6 2.6 to 10.6 6 (roughly 100 to 150 pg/mL) [3–6]. Existing clinical studies
1.1 mg/L in the IV group (P 5 0.007). Serum calcium increased
indicate that PTH secretion may be difficult to suppresssignificantly in all groups from 8.4 6 0.25 to 9.0 6 0.28, 8.5 6
in patients with severe disease [7]. Therefore, early atten-0.16 to 9.2 6 0.27, and 8.7 6 0.16 to 9.4 6 0.18 mg/dL in the
calcium, oral, and IV groups, respectively (P 5 NS difference tion to the derangement in mineral metabolism leading
between groups). Serum phosphorus was significantly lower in to parathyroid overactivity is indicated. Such early aggres-
the calcium group throughout the study (P 5 0.02). Hypercalce- sive therapy of mild hyperparathyroidism, however, hasmic episodes were 2.0 6 0.8, 3.0 6 0.6, and 3.4 6 0.6 per
the potential to oversuppress PTH and lead to adynamicpatient-year (P . 0.10), and hyperphosphatemic episodes were
bone disease [8]. The optimal therapy of mild secondary
HPT necessary to lower circulating PTH levels and main-
1 In addition to O.S.I and L.D.Q., the Durham Renal Osteodystrophy
tain normal bone remodeling has not been defined.Group consists of Drs. Eugene Kovalik, David Butterly, Michael Ber-
koben, Steven Schwab, Stephen Smith, and Robert Gutman. The use of intravenous calcitriol in combination with
calcium supplements has gained widespread acceptance
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in the management secondary HPT in patients withline phosphatase, secondary hyperparathyroidism, dialysis, adynamic
bone disease. ESRD. Whereas this approach corrects calcitriol defi-
ciency and prevents parathyroid gland hyperplasia andReceived for publication February 8, 1999
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with the development of adynamic bone disease [8]. Al- over a year, subjects younger than 18 years old, pregnant
patients, those with HIV disease, subjects with aluminumthough calcium supplementation alone is considered to
be inadequate for treatment of established hyperpara- overload (serum aluminum concentration above 80
mg/L) and iron overload (serum ferritin levels abovethyroidism [11], it may be an effective treatment of mild
secondary HPT [12]. Considering the potential complica- 1000 ng/mL), and those with a history of parathyroidec-
tomy. We also excluded subjects who were hypercalce-tions of intensive calcitriol therapy, a less intensive treat-
ment might have important benefits in such patients. mic (serum calcium above 10.5 mg/dL without calcium
or calcitriol treatment), had received therapy with vita-Other approaches, including daily physiologic replace-
ment of calcitriol, may also show a favorable treatment min D analogues within the past two months, as well
as subjects being treated with steroids, phenytoin, orand side-effect profile compared with intensive pharma-
cologic dosing of intravenous calcitriol in patients with phenobarbital. In addition, subjects who were unlikely
to be able to finish the full 40 weeks of the study basedmild secondary HPT [13, 14]. There are no randomized
controlled studies, however, directly comparing these on serious coexisting diseases, plans for transplantation
or transfer to other dialysis modalities or other dialysisdifferent treatment strategies in the management of
ESRD patients with mild secondary HPT. units, and those receiving inadequate dialysis therapy
(Kt/V less than 1.0 or urea reduction ratio less than 55%)To evaluate the need for calcitriol and compare various
approaches to manage mild secondary HPT in patients were excluded.
initiating hemodialysis, we performed a prospective ran-
Run-in perioddomized trial comparing treatment with oral calcium
carbonate (CaCO3) alone in escalating doses, with two The purpose of the four-week run-in period was to
standardize the diet, calcium intake, and dialysate cal-calcitriol regimens consisting of either daily oral replace-
ment or intermittent intravenous (IV) administration, cium, as well as to lower serum phosphorus concentra-
tions to below 6.6 mg/dL. In the beginning of this period,along with fixed doses of CaCO3. In this study, suppres-
sion of serum PTH was the primary end point for as- the dialysate calcium concentration was standardized at
2.5 mEq/L (1.25 mmol/L). All subjects were instructedsessing parathyroid gland function, and changes in circu-
lating plasma bone-specific alkaline phosphatase (BAP) about how to change their diet to contain 500 to 600 mg
of elemental calcium and 800 to 900 mg of phosphoruswere the secondary outcomes used to assess the effect
of treatment on bone metabolism [15–17]. Finally, we per day. In addition, the existing calcium supplementa-
tion was discontinued, and the subjects were started oncompared tolerance with therapy by monitoring episodes
of hypercalcemia and hyperphosphatemia. CaCO3 therapy (Oscal-500; SmithKline Beecham, Phila-
delphia, PA, USA). The dose of CaCO3 was determined
by the initial serum calcium and phosphorus concentra-
METHODS
tion in the following manner. Subjects with normal serum
Study design calcium (8.7 to 10.5 mg/dL) and phosphorus (2.3 to 4.5
mg/dL) levels were given 1500 mg of elemental calciumThis was a prospective, randomized, nonmasked clini-
cal trial designed to compare three different therapies of per day in three divided doses (one pill of Oscal-500
three times a day with meals). Those with a calcium con-mild secondary HPT in patients initiating hemodialysis
therapy: CaCO3 alone in escalating doses (calcium centration below 8.7 mg/dL and/or a phosphorus concen-
tration above 4.5 mg/dL were given 2500 mg elementalgroup), daily oral calcitriol (oral group), and three times
weekly intravenous calcitriol (IV group). The calcitriol calcium per day in divided doses (one pill with breakfast,
two with lunch, and two with dinner). An aluminum-groups received CaCO3 in fixed doses. The study was 40
weeks in duration and was divided into a four-week run- containing phosphorus binder was added in doses of up
to 3 g aluminum hydroxide per day, given with meals,in period and a 36-week treatment period.
if serum phosphorus remained above 6.6 mg/dL. If phos-
Subjects phorus control was not adequate at the end of the run-
in period, an additional week was allowed after enforce-We recruited patients with mild secondary HPT ini-
tiating maintenance hemodialysis therapy at five dialysis ment of medication and diet. At the time of the study,
aluminum-containing phosphate binders were the com-units affiliated with Duke University Medical Center and
Durham Regional Hospital between November 1994 and pounds most frequently prescribed for hyperphosphate-
mia for patients where calcium salts were not adequateJuly 1996. To identify the patients, we examined the
initial intact PTH level measured at the respective dial- or tolerated in the management of hyperphosphatemia.
The dose was limited to 3 g aluminum hydroxide toysis unit for every patient starting dialysis therapy during
this period. Those with a serum intact PTH concentration minimize potential toxicity. This dose has been shown
to not result in bone accumulation of aluminum withbetween 150 and 600 pg/mL were eligible for our study.
Subjects were excluded who had been on dialysis for short-term usage [18].
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Treatment period increased every two to four weeks to raise calcium to
the 10.0 to 10.5 mg/dL range. In the oral group, incre-At the end of the run-in period, 52 patients were ran-
ments were in steps of 0.25 mg every day (1.75 mg/week)domized (11 into the calcium group, 20 into the oral
and in the IV group in steps of 0.5 mg per dialysis treat-group, and 21 into the IV group) and followed for up to
ment (1.5 mg/week). If serum calcium levels rose above36 weeks. After randomization, we used serum calcium
10.5 mg/dL, initially the calcitriol dose was decreased bylevels to guide the therapy. Our goal was to achieve
50% if the calcium concentration was below 11.1 mg/dL. Ifserum calcium levels in the 10.0 and 10.5 mg/dL range.
the serum calcium level was between 11.0 and 12.0 mg/dL,To obtain that goal in the calcium group, we increased
calcitriol was held until the calcium was below 10.5 mg/dLthe dose of CaCO3, whereas in the other groups, the
and was then started at half of the previous dose. If serumdose of CaCO3 was maintained at the run-in dose and
calcium was over 11.9 mg/dL and/or if symptomatic hy-calcitriol dose titrated to increase the serum calcium to
percalcemia developed, both CaCO3 and calcitriol werethe desired range. The dialysate calcium concentration
held and restarted once the calcium level was below 10.5remained at 2.5 mEq/L throughout the study period. As
mg/dL, CaCO3 at the same dose but calcitriol at half thethis study was nonmasked, we followed a strict a priori
previous dose. If patients developed hyperphosphatemiadefined treatment protocol to avoid biases in the inten-
during treatment with calcitriol, we initially increasedsity of therapy. In addition, the person making decisions
the CaCO3 2500 mg elemental calcium per day if patientsregarding treatment changes (L.D.Q.) was blinded to the
were taking a lower dose than that and the serum calciumcurrent PTH level and calcitriol group assignment. Dietary
was less than 10.5 mg/dL. If the phosphate level remainedcompliance was monitored monthly with a 24-hour diet
higher than 6.5 mg/dL or if subjects were already takingrecall and was enforced by dietitians at the respective
this maximal allowed amount of calcium, we addeddialysis units. Compliance with study medications was
Al(OH)3 with meals in doses of up to 3.0 g per day.monitored by the physician coordinating the study, inter-
If hyperphosphatemia persisted, the calcitriol dose wasmittent pill count, frequent enforcement, and final com-
reduced every two weeks in 50% decrements each time.
pliance calculated from the total count of pills per bottles
Protocol deviations. One subject in the calcium group
delivered to patients during the study. Compliance with received three weeks of treatment with intravenous
calcitriol in the IV group was calculated from missed calcitriol, 0.5 mg with each dialysis, between weeks 6 and
hemodialysis treatment during the study period. 9 of the study period. Leaving this subject out of the
At the beginning of the study period, the calcium analysis did not alter the results and is therefore included
group received CaCO3 in a dose of 2.5 g elemental cal- without changes. The calcitriol was mistakenly stopped
cium per day. To raise serum calcium to 10.0 to 10.5 mg/dL, at week 28 of the study period for one subject in the
we increased the daily dose of CaCO3 by 1250 to 2500 mg oral group, but the protocol was reinstated at week 33.
every two to four weeks. If hypercalcemia developed, This patient was followed for an additional four weeks,
the dose was reduced by 25% if serum calcium was in and ending values were measured at week 40. Four pa-
the range of 10.6 to 11.0 mg/dL, and the dose reduced tients, three in the IV and one in the oral group, dropped
by 50% if serum calcium was between 11.0 and 12.0 mg/dL. out of the study prior to 24 weeks. One of these moved
If serum calcium was above 11.9 mg/dL and/or symptom- away, and one died from cerebrovascular accident two
atic hypercalcemia developed, CaCO3 was held and re- weeks into the study period. No intact PTH measure-
started at 50% of previous dose once serum calcium ments were available from the study period for these
was below 10.5 mg/dL. If phosphorus was not controlled subjects, and they are excluded from all analyses. The
under 6.6 mg/dL with this CaCO3 regimen, Al(OH)3 was third patient died from staphylococcal septicemia after
added and taken in divided doses with meals up to a 18 weeks of study. The one subject in the oral group
maximum of 3 g/day. If sustained hypophosphatemia withdrew from the study after six weeks, complaining
occurred (serum phosphorus below 2.0 mg/dL on two of upset stomach from oral calcitriol. Two additional
subsequent measurements), the CaCO3 dose was de- patients in the IV group moved away after 24 and 28
creased to the last tolerated dose. Throughout the study, weeks of study, and three subjects (one in each group)
CaCO3 was prescribed with meals. chose to end the study after 28 weeks of therapy to
In the calcitriol groups, CaCO3 intake at randomiza- participate in another study unrelated to ours but
tion was kept fixed at the run-in dose, and calcitriol that excluded continued participation. One subject (IV
treatment was initiated. In the oral group, calcitriol group) was hospitalized for severe diverticulitis requiring
(Rocaltrol; Hoffman-La Roche, Nutley, NJ, USA) was surgical intervention, after 32 weeks of the study period,
started at a dose of 0.5 mg at bedtime each day (3.5 mg/ and was withdrawn from the study at that time. Thus,
week), and in the IV group (Calcijex; Abbott, Abbott 48 patients (11 calcium, 19 oral, and 18 IV groups) fin-
Park, IL, USA), an initial dose of 1 mg after each dialysis ished 24 weeks of the study period, and 42 (10 calcium,
18 oral, and 14 IV) finished the full 36 weeks.treatment (3 mg/week) was given. The calcitriol dose was
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Biochemistry parison of the calcium group with the oral group. We
chose to perform these pair-wise comparisons to pre-All blood was drawn on the first dialysis session of
serve optimal power to detect possible differences be-each week and centrifuged within two hours, and the
tween these groups. Secondary end points, analyzed inserum was frozen at 2208C until biochemical measure-
the same pair-wise manner, were the ending BAP levelments were performed. These were done on a weekly
and the incidence of hypercalcemia and hyperphosphate-basis for calcium and phosphorus and every month for
mia, as well as the time-dependent pattern of PTH andthe other biochemical parameters, except for BAP,
BAP response.which was measured in batches throughout the study.
We used analysis of covariance (ANCOVA) to com-During the run-in period and the initial four weeks of
pare the groups in this pair-wise manner with regard tothe study period serum, calcium and phosphorus levels
the ending PTH level, incorporating initial PTH level(Hitachi 911 autoanalyzer) were measured every week.
as a covariate to control for baseline PTH differences.After that, serum calcium and phosphorus were moni-
Similarly, ANCOVA was used to compare the endingtored every four weeks as well as weekly for two weeks
BAP, using the initial BAP as a covariate. Fisher’s exactfollowing change in dosage of any of the study medica-
test and Wilcoxon rank sum test or two-sample t-testtions. Serum albumin and bicarbonate concentrations
were used to compare the groups with regard to categori-(Hitachi 747-200 autoanalyzer) were measured every
cal and continuous variables as appropriate. Simple com-four weeks at the respective dialysis units. Serum intact
parisons of before and after treatment values withinPTH level (immunoradiometric assay; Nichols Institute,
groups were done using the paired t-test; however, toSan Juan Capistrano, CA, USA) was measured at the
examine the time-dependent changes in PTH and BAPbeginning of the run-in period and at weeks 0, 4, 8, 12, 16,
levels, repeated-measures analysis of variance allowing24, and 36 of the study period. Serum BAP concentration
for missing data. An additional variable included in the(immunoradiometric assay, Hybritec; normal subjects,
post hoc analysis of the PTH and BAP response wasmean 6 2 sd, 11.8 6 8.6 mg/L; minimum detectable
compliance with medical treatment. In the analysis ofconcentration, 2.0 mg/L) was measured at weeks 0, 12,
ending PTH, BAP, calcium, and phosphorus concentra-24, and 36 of the study period. The serum aluminum
tion, we used data from the 48 patients finishing at leastconcentration (graphite furnace; Perkin-Elmer, Nor-
24 weeks of study, as the PTH levels had already reachedwalk, CT, USA) was measured at the beginning of the
a plateau at 24 weeks (Fig. 1). The last available measure-run-in period and at the end of the study. Serum 1,25-
ment of these variables served as the ending PTH leveldihydroxyvitamin D concentration (Radioreceptor assay;
in the analysis. The 50 patients with available PTH andIncstar Corporation, Stillwater, MN, USA) was mea-
BAP measurements at any time during the study periodsured at the beginning and end of the study period. For
were used for all other analyses. Data are presented assubjects who left the study early, we used the last available
mean 6 sem unless otherwise noted.sampling time to do the study end measurements.
Statistical analysis
RESULTS
Patients were randomized into the three treatment
Baseline characteristicsgroups using a permuted block randomization scheme,
There was no statistical difference between the groupsbased on our a priori power calculations. The primary
with regard to age, gender, or primary disease (Table 1).end point on which power calculations were based was
Ninety-two percent of our patients were African Ameri-the ending PTH level. Preliminary analysis in subjects
can, reflecting the dialysis population in the participatingat the participating dialysis units indicated the mean 6
dialysis units. The time patients had been on dialysissd of serum intact PTH to be 300 6 100 pg/mL in this
before enrolling into the study was similar between thepopulation. We assumed limited effect of calcium [11]
groups. In concordance with our intention to recruit pa-and a greater PTH suppression with pharmacologic than
tients with mild secondary HPT, the mean baselinephysiologic doses of calcitriol, predicting ending PTH to
(time 0) intact PTH level was 303 6 18.1 pg/mL in thebe 240 6 75 in the calcium group, 100 6 75 in the oral
group as a whole. Overall, 54% of patients had serumgroup, and 35 6 25 pg/mL in the IV group. To optimize
calcium below the lower limit of normal (8.7 mg/dL)the power of the study based on these assumptions, 10
with even distribution between the groups. Baselinepatients were needed in the calcium group and 20 in
phosphorus was slightly lower in the calcium group; how-each calcitriol group. This gave a power in excess of 90%
ever, this difference was not statistically significant. Base-to detect the proposed differences between the groups at
line differences between treatment groups in PTH anda significance level of 0.025 adjusting for the two primary
other biochemical parameters were not statistically sig-comparisons. These primary comparisons were (1) a
comparison of the two calcitriol groups and, (2) a com- nificant (Table 1).
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Table 1. Baseline characteristics of patients in the three groups
Treatment group
Calcium carbonate Oral calcitriol Intravenous calcitriol
(N 5 11) (N 5 20) (N 5 19)
Demographics
Age years 60.163.36 54.6 63.29 53.3 63.30
Race black/white 11/0 17/3 18/1
Gender female/male 8/3 7/13 6/13
Primary disease diabetes/other 5/6 11/9 8/11
Time on dialysis at enrollment weeks 12.563.45 9.7 62.3 12.761.97
Baseline biochemistry
Serum aluminum lg/L 13.563.25 10.8 61.34 11.6 62.14
Serum albumin mg/dL 3.860.13 3.7 60.08 4.0 60.07
Serum bicarbonate mEq/mL 21.160.91 20.6 60.82 20.4 60.66
Serum 1,25(OH)2D3 pg/mL 11.962.28 10.7 61.14 14.8 62.92
Serum intact PTH pg/mL 325646.2 265 626.4 240 627.7
Serum BAP lg/L 20.767.60 20.6 63.89 19.1 62.61
Serum calcium mg/dL 8.460.25 8.5 60.16 8.7 60.16
Serum phosphorus mg/dL 4.060.4 4.6 60.38 4.7 60.23
Kt/V 1.3760.07 1.33 60.06 1.34 60.04
Abbreviations are: BAP, bone-specific alkaline phosphare; PTH, parathyroid hormone.
There were no statistically significant differences between the groups.
Interventions and biochemical parameters during the
run-in period
During the run-in period, phosphorus was controlled
below 6.5 mg/dL in all subjects with mean CaCO3 doses
that averaged 2.3 g of elemental calcium (Table 2). Four
subjects were subsequently randomized into the IV
group, three who were randomized into the oral group,
and one who was randomized into the calcium group also
needed the addition of low doses of aluminum phosphate
binders to achieve control of serum phosphorus (Table
2). The mean serum calcium did not change significantly
over the run-in period, and there were only mild decre-
ments seen in both the serum phosphorus concentration
and intact PTH levels in the group as a whole (Figs. 1
and 2). There was not a statistically significant difference
in the changes in calcium, phosphorus, and intact PTH
over this period between subjects who were subsequently
randomized into the three groups. There were also no
differences in the doses of CaCO3 and aluminum hydrox-
ide during the run-in period (Table 2).
Therapeutic interventions
By design, the calcium dose was kept constant in the
two groups treated with calcitriol, and the average pre-
scribed doses in the oral and IV groups were 2236 6
93.1 and 2300 6 81.5 mg elemental calcium per day,
respectively. Subjects in the calcium group received esca-
lating doses of CaCO3 to increase serum calcium concen-
Fig. 1. Changes in serum intact parathyroid hormone (PTH) levels in trations (Table 2). The mean dose at the beginning of
response to treatment with calcium carbonate (e, N 5 11), daily oral the study period was 2327 6 95.4 mg of elemental calciumcalcitriol (j, N 5 20), and intermittent intravenous calcitriol (h, N 5
(5817.5 mg CaCO3, 4.6 pills) per day, and the mean19). This is an analysis of all patients showing parallel decrements in
mean intact PTH levels in the three groups. There was not a statistically prescribed dose was highest at the end of the study,
significant difference in PTH response between the calcium carbonate 7150 6 1325.1 mg of elemental calcium per day (Table 2).and the oral calcitriol group nor between the two calcitriol groups when
controlled for initial PTH levels. The mean daily dose of elemental calcium prescribed
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for the calcium group during the study was 5399 6 642.2 in the analysis of the calcitriol groups. The difference
between treatment groups continued to be nonsignificantmg (Table 3).
Prescribed calcitriol doses were slightly higher in the in that model (P 5 0.78). When the four patients in the
oral group with a calcitriol compliance rate of less thanIV than in the oral group, reaching statistical difference
between weeks 4 and 12 (P , 0.05, Wilcoxon rank-sum 60% were left out, the PTH suppression curve was almost
identical to the IV group, and ending PTH for the compli-test). This difference was not statistically significant at
any other time point (Table 2). Moreover, the total cu- ant patients in the oral group was 92 6 13.5 pg/mL.
Medical compliance was also an important predictor ofmulative prescribed dose was similar between these
groups (Table 3). The maximal tolerated dose of calcitriol PTH response when comparing the calcium and the oral
groups (P 5 0.0006), followed by initial PTH level (P 5was seen between weeks 8 and 12 in both groups, 4.2 6
0.51 and 5.2 6 0.44 mg/week in the oral and IV groups, 0.02), whereas the effect of treatment remained insig-
nificant in the model. In addition, there were no time-respectively (Table 2).
Within eight weeks, we were able to stop the Al(OH)3 dependent differences between the groups by pair-wise
repeated-measure analysis of variance (ANOVA), con-in the one patient in the calcium group needing it to
control serum phosphorus. In contrast, 13 subjects in the trolling for initial PTH level and/or compliance.
Bone-specific alkaline phosphatase response. In theoral and 12 subjects in the IV groups needed Al(OH)3
to control the serum phosphorus concentration during calcium group, the mean BAP concentration increased
from 20.7 6 7.60 to 27.5 6 7.00 mg/L (P 5 0.17, pairedthe treatment period. Consequently, there was a signifi-
cant difference between the Al(OH)3 dose between the t-test), whereas in the other groups, it decreased from
20.6 6 3.89 to 17.8 6 4.54 mg/L in the oral group (P 5calcium group and the others, whereas prescribed doses
were similar in the calcitriol groups, with an average 0.26) and from 19.1 6 2.61 to 10.6 6 1.09 mg/L in the
IV group (P 5 0.007). By ANCOVA, using the initialdose of 1044 6 230.1 and 980 6 232.8 mg/day in the oral
and IV groups, respectively (Table 3). BAP as a covariate, there was no statistically significant
difference in the ending BAP level between the oral and
Estimates of compliance the IV calcitriol groups (P 5 0.18, Bonferroni’s correc-
tion). The same was true for repeated-measure ANOVAThe compliance with the active treatment, CaCO3 in
the calcium group, and calcitriol in the others differed comparing time-dependent changes in BAP between the
two calcitriol groups. There was also no statistically sig-significantly in that compliance was better in the IV than
the others, 95% vs. 81% in the oral (P , 0.02, Wilcoxon nificant difference in ending BAP concentration between
the calcium and the oral groups (P 5 0.10, Bonferroni’srank sum test) and 70% in the calcium group (P ,
0.0002). The difference between the oral group and the correction) when controlled for the initial BAP level.
However, using repeated-measure ANOVA, taking intocalcium group was of borderline significance (P 5 0.07).
This difference in compliance did not result in a statisti- account the response to treatment over time, there was
a statistically significant difference between the calciumcally significant difference in dose of calcitriol (P 5 0.11,
Wilcoxon rank sum test; Table 2) between the two group and the oral group even after controlling for the
initial BAP level (P 5 0.05). Thus, both oral and IVcalcitriol groups. Compliance with CaCO3 in the calcitriol
groups and Al(OH)3 in all three groups was in the range calcitriol suppress BAP to a greater extent than calcium
alone. Moreover, five patients in the oral calcitriol groupof 67 to 81% and did not differ significantly between the
groups (Table 3). and six in the IV group had a serum BAP concentration
in the low normal range (,7.5 mg/L, mean 2 1 sd, 15%
Changes in biochemical parameters in response of normal subjects) at the end of the study.
to treatment Other biochemical parameters. Calcium increased sig-
nificantly in all groups (P , 0.05, paired t-test), and thereParathyroid hormone response. PTH levels decreased
significantly in all groups (P , 0.01, paired t-test), and was no statistical difference between the groups with re-
gard to baseline and ending calcium concentration. Serumthis decrease was most pronounced in the IV group
(Fig. 1). The mean ending PTH levels were 160 6 44.5, calcium increased from 8.4 6 0.25 to 9.0 6 0.28, 8.5 6
0.16 to 9.2 6 0.27, and 8.7 6 0.16 to 9.4 6 0.18 mg/dL in125 6 23.7, and 65 6 10.0 pg/mL in the calcium, oral,
and IV groups, respectively. The ANCOVA, using initial the calcium, oral, and IV groups, respectively (Fig. 2A).
There was a dramatic difference in the serum phosphorusintact PTH level as a covariate, showed no statistically
significant difference in ending PTH between the oral concentration between the calcium group and the others
over the study period that was largely due to a declineor IV calcitriol groups (P 5 0.13, Bonferroni’s correc-
tion) or between the calcium and the oral calcitriol in serum phosphorus in the calcium group (Fig. 2B). In
both calcitriol groups, there was a mild increase in serumgroups (P 5 0.72). Compliance with calcitriol treatment
was also an important predictor of the ending PTH level phosphorus over time from 4.6 6 0.38 to 4.9 6 0.32 mg/dL
in the oral group and from 4.7 6 0.23 to 5.2 6 0.28(P 5 0.0008) when it was added as another covariate
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Table 2. Mean prescribed doses of CaCO3, calcitriol and Al(OH)3 in the three groups averaged over four week intervals throughout the study
Control period, weeks Study period, weeks
24 to 0 0 to 4 4 to 8 8 to 12 12 to 16
Elemental Calcium, mg/day
Group
Calcium carbonate 2327695 4034 6260a 48866332a 52276474a 56486626a
Oral calcitriol 2290677 2169 6105 21316123 22766106 22506114
Intravenous calcitriol 2303682 2289 696 2329686 2309689 2303691
Calcitriol, lg/week
Group
Calcium carbonate 0 0 0 0 0
Oral calcitriol 0 3.760.1 4.160.41b 4.260.51b 3.960.62
Intravenous calcitriol 0 3.260.01 4.360.32 5.260.44 4.660.55
Al(OH)3, mg/day
Group
Calcium carbonate (1)c 136 170 113 0a 0a
Oral calcitriol (13)c 131674 318 6136 7626249 11976295 12896311
Intravenous calcitriol (12)c 2366124 526 6203 8296257 10536284 11386301
a Statistically significant difference between the calcium carbonate group and the other groups
b Statistically significant difference between the oral calcitriol and intravenous calcitriol groups
c Indicates number of patients receiving aluminum hydroxide at some point during the study
mg/dL in the IV group. This increase was significant in episode of hypercalcemia, compared with 15 out of 20
in the oral group and 17 out of 19 in the IV group. Therethe IV group only (P 5 0.03, paired t-test). However,
the rise in serum phosphorus was limited by the addition were also fewer hypercalcemic episodes in the calcium
of aluminum-containing phosphorus binders in roughly group compared with the others, 2.0 6 0.80 episodes per
65% of patients, and in the absence of increased phos- patient-year, whereas there were 3.0 6 0.56 and 3.4 6
phate binding, this rise would likely have been greater. 0.55 episodes per patient-year in the oral and the IV
In contrast, the calcium group demonstrated a consistent groups, respectively. These differences were not statisti-
decrease in serum phosphorus over the study period cally significant. All these episodes were asymptomatic.
without the additional use of aluminum-containing phos- With regard to phosphorus, hyperphosphatemia (serum
phorus binders. In this group, serum phosphorus de- phosphorus concentration .6.5 mg/dL) developed at
creased from 4.0 6 0.35 to 3.5 6 0.42 mg/dL. Moreover, some point in 3 out of 11 patients in the calcium group
ANOVA showed a significant difference between the compared with 15 out of 20 in the oral group and 16 out
ending serum phosphorus concentration in the calcium of 19 patients in the IV group, and there were only 0.9 6
group and the other groups, even when accounting for 0.56 episodes of hyperphosphatemia per patient-year in
differences in baseline serum phosphorus levels (P 5 0.02, the calcium group compared with 4.2 6 0.79 and 4.9 6
Bonferroni’s correction). Over the study, serum aluminum 0.84 in the oral and IV groups, respectively. This differ-
changed significantly in the IV group only, increasing ence between the calcium group and the calcitriol groups
from 11.6 6 2.14 to 21.9 6 3.15 mg/L (P 5 0.03, paired was highly significant (P , 0.01). On the other hand,
t-test), whereas in the oral group, it increased from 10.8 6 hypophosphatemia (serum phosphorus concentration
1.34 to 15.7 6 3.06 mg/L (P 5 0.17), and in the calcium ,2.0 mg/dL)-limiting CaCO3 administration was seen in
group, serum aluminum decreased from 13.5 6 3.25 to two patients in the calcium group.
11.0 6 1.36 mg/L (P 5 0.45). The serum 1,25(OH)2D3
concentration increased slightly in both calcitriol groups
DISCUSSIONfrom 10.7 6 1.14 to 13.2 6 2.70 pg/mL in the oral group
The primary goal of our study was to assess the needand from 14.8 6 2.92 to 15.9 6 2.76 pg/mL in the IV
for calcitriol and to compare different calcitriol regimensgroup. This was, however, not statistically significant, likely
in the treatment of mild uremic hyperparathyroidism.reflecting that these measurements were trough levels.
To accomplish this, we compared three treatment groups.In contrast, there was a significant decrease in serum
One group received CaCO3 alone, given in escalating1,25(OH)2D3 concentration in the calcium group from
doses. The other two groups were treated with a fixed11.9 6 2.28 to 6.5 6 0.64 pg/mL (P 5 0.02, paired t-test).
dose of CaCO3 and daily oral or intermittent intravenous
Incidence of hypercalcemia and hyperphosphatemia calcitriol therapy in increasing doses. This permitted the
upward titration of serum calcium levels by distinct treat-There was a propensity for less hypercalcemia (serum
ment regimens, namely, either CaCO3 or calcitriol, andtotal calcium concentration .10.5 mg/dL) in the calcium
group, where 6 out of 11 patients developed at least one was designed to independently assess the effects of oral
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Table 2. continued
Study period, weeks
16 to 20 20 to 24 24 to 28 28 to 32 32 to 36
Elemental Calcium, mg/day
Group
Calcium carbonate 59666726a 61486940a 637561058a 684161160a 715061325a
Oral calcitriol 2276 6106 2303 6102 2316 6103 2322 695 2291 693
Intravenous calcitriol 22896105 2319 690 2319 690 2265 6106 2172 6126
Calcitriol, lg/week
Group
Calcium carbonate 0 0 0 0 0
Oral calcitriol 3.8 60.64 3.6 60.72 4.0 60.66 3.8 60.75 3.6 60.77
Intravenous calcitriol 4.460.60 4.1 60.62 4.1 60.67 4.1 60.80 3.6 60.81
Al(OH)3, mg/day
Group
Calcium carbonate (1)c 0a 0a 0a 0a 0a
Oral calcitriol (13)c 13556308 1329 6309 1447 6298 1565 6312 1674 6302
Intravenous calcitriol (12)c 11456294 1160 6297 1194 6310 1309 6309 1281 6338
Fig. 2. Changes in serum calcium (A) and phosphate (B) concentration in response to treatment with calcium carbonate (e, N 5 11), daily oral
calcitriol (j, N 5 20), and intermittent intravenous calcitriol (h, N 5 19). (A) The mean serum calcium concentration increased significantly in
all groups (P , 0.05), and there was no statistical difference between the groups. (B) Mean serum phosphorus increased slightly in both calcitriol
groups in spite of use of Al(OH)3 in 65% of patients in both groups. However, there was a significant decrease in mean serum phosphorus in the
calcium group, and mean serum phosphorus levels were significantly different from both calcitriol groups during the study.
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Table 3. Mean cumulative and average prescribed doses and compliance with CaCO3, calcitriol and Al(OH)3 in the three groups
Mean Compliance
cumulative dose Average dose % of prescribed
Elemental calcium group (g) (mg/day)
Calcium carbonate 15066188.2a 53996642.2a 70b
Oral calcitriol 608 635.5 2236693.1 76
Intravenous calcitriol 611626.4 2300681.5 81
Calcitriol group (mg) (mg/week)
Calcium carbonate 0 0 —
Oral calcitriol 133 617.0 3.960.45 81b
Intravenous calcitriol 144615.8 4.260.43 95
Al(OH)3 group (g) (g/day)
Calcium carbonate (1)c 13a 44a 71
Oral calcitriol (13)c 294665.0 10446230.1 67
Intravenous calcitriol (12)c 255662.0 9806232.8 76
a Statistical difference between the calcium carbonate group and the other groups
b Statistical difference compared to the compliance with active treatment (calcitriol) in the intravenous calcitriol group
c Indicates number of patients receiving aluminum hydroxide at some point during the study
calcium and calcitriol to suppress PTH. We found that all supplementation. 1,25(OH)2D3 levels were also low and
decreased significantly in our CaCO3-treated patientsthree treatments suppressed serum PTH concentrations,
with mean PTH levels decreasing in parallel fashion in and are therefore not likely to explain the treatment
response. A shorter duration of disease and the excellentthe three groups during the 36-week study period (Fig. 1).
There were no statistical differences between the groups phosphorus control are more likely to be responsible
for the favorable PTH response. Indeed, recent studieswith regard to beginning or ending PTH levels. More-
over, time-dependent changes in serum PTH levels, as indicate a direct stimulatory effect of hyperphosphate-
mia on the parathyroid gland [22, 23]. Regardless, ourassessed by repeated-measure ANOVA, were compara-
ble between the groups. findings that calcitriol administration may not be neces-
sary in patients with mild secondary HPT are consistentOur finding that PTH response was similar in the
calcitriol groups is consistent with results from several with another randomized study demonstrating control of
hyperparathyroidism by calcium administration withoutrandomized controlled trials studying patients with more
advanced secondary HPT [7, 19, 20]. Our results now concomitant treatment with calcitriol [12].
With regard to biochemical markers of bone forma-extend those findings to patients with mild secondary
HPT and, additionally, quantitate the effect of medical tion, we found a difference between the calcium and the
calcitriol groups with regard to BAP. The BAP de-compliance, which was an important factor in predicting
PTH response. Thus, our study adds further support creased in both calcitriol groups but increased in the
calcium group, and this difference was statistically sig-to the view that there are no important differences in
therapeutic outcome related to the route of calcitriol nificant by the repeated-measure ANOVA. The dispa-
rate response in PTH and BAP might reflect a cumulativeadministration and the consequent differences in peak
calcitriol levels resulting from intravenous and oral ad- effect of transient PTH suppression of greater magnitude
in the calcitriol-treated groups, a possible effect of phos-ministration [21].
In contrast, our finding that calcium supplementation phorus on PTH resistance of bone [24], or more likely,
a direct effect of calcitriol to suppress bone turnoveralone can significantly reduce PTH levels was unex-
pected and differs from an earlier noncontrolled study independent of PTH [8, 25]. Regardless, within the limi-
tations of the BAP assay [16, 17], the observation of lowshowing that CaCO3 by itself is not adequate to optimally
treat uremic secondary HPT [11]. It is possible that the normal BAP levels in a high proportion of patients in
the calcitriol groups indicates a tendency of calcitriolamount of CaCO3 administered, the presence of hypocal-
cemia, the milder degree of hyperparathyroidism or treatment to oversuppress bone turnover. This potential
for oversuppression was observed with pharmacologicalshorter duration of ESRD, persistent endogenous pro-
duction of 1,25(OH)2D3 during the initial months on he- dosing of calcitriol as well as with daily oral replacement
therapy, and may signify development of adynamic bonemodialysis, and better control of serum phosphorus con-
centrations contribute to the greater effectiveness of disease. Our study design allowed us to evaluate the
relative potency of each therapy by adjusting the therapycalcium alone to suppress PTH levels in our study. How-
ever, mean initial calcium levels were similar in our study to maintain the serum calcium concentration in the high
normal rather than setting a specific target range forcompared with the others, indicating that we had not
selected out a group more likely to respond to calcium PTH. In clinical practice, it is more appropriate to adjust
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the treatment to avoid reduction of PTH and BAP to centration over the study period associated with Al(OH)3
use in the IV calcitriol groups is of concern. Even thoughlevels consistent with adynamic bone disease, for exam-
short-term use of low-dose Al(OH)3 has not been associ-ple, PTH of 100 to 150 pg/mL and BAP of 5 to 12 mg/L
ated with bone accumulation of aluminum [18, 32], it[16, 17, 26, 27].
may result in increases in serum and desferoxamine-There were no differences in serum calcium concentra-
induced serum aluminum concentration [32]. Because oftions between the various treatment groups during the
its potential toxicity [29], its use should be limited tostudy, and the incidence of hypercalcemia was also simi-
refractory hyperphosphatemia and replaced by new non-lar. The fact that all groups showed significant increases
aluminum/noncalcium phosphate binders where possible.in mean serum calcium reflects the success of either high-
Other potential confounding factors include diabetes anddose CaCO3 or low-dose CaCO3 with calcitriol treatment
gender. However, there was not a significant differenceto achieve similar effects on calcium homeostasis (Fig.
between the groups with regard to diabetes and gender2A). In contrast, we observed superior phosphorus con-
distribution; therefore, such confounding is unlikely.trol and significantly fewer episodes of hyperphosphate-
In conclusion, all three treatments suppress PTH levelsmia (serum phosphorus .6.5 mg/dL) in the calcium
in ESRD patients with mild hyperparathyroidism, butgroup compared with the calcitriol-treated patients, in
each of these management strategies has clinically im-spite of frequent use of Al(OH)3 in the calcitriol groups.
portant differences in efficacy and safety profiles thatThe reduced risk of hyperphosphatemia in the calcium
may influence their use. CaCO3 therapy alone suppressesgroup is consistent with the diminished gastrointestinal
intact PTH levels to an acceptable range, optimally con-absorption of phosphorus in the absence of calcitriol as
trols serum phosphorus levels, but appears to have lesswell as the greater dietary phosphate binding achieved
osseous effects. In contrast, calcitriol therapy, both phar-with the high doses of CaCO3 [28].
macological dosing with intermittent intravenous admin-This study was designed to optimize detection of dif-
istration and daily oral physiological replacement haveferences in PTH response between the groups (discussed
a more suppressive effect on BAP and may have a moreearlier in this article). Consequently, our treatment regi-
consistent effect on PTH as well. Both calcitriol regimensmen of fixed calcium doses in the calcitriol treated groups
cause frequent hypercalcemia and hyperphosphatemia,does not conform to the more flexible adjustments of
requiring the addition of non-calcium-containing phos-calcium and calcitriol doses in clinical practice. Neverthe-
phate binders. Given the importance of hyperphosphate-less, our results suggest that calcitriol treatment may not
mia in parathyroid gland dysfunction [23], soft tissuebe necessary to achieve control of PTH to acceptable
calcifications [33] and possibly mortality of dialysis pa-levels in patients with mild secondary HPT. In addition,
tients [34], CaCO3 in the absence of calcitriol seems tobased on our a priori assumptions of limited response
be an appropriate initial therapy. However, possibleto calcium therapy alone, on which we based our power
differential effects on bone, caused by the lack of
calculations, our study may be underpowered to detect 1,25(OH)2D3, and long-term consequences of positivea difference between the calcium and calcitriol groups. calcium balance, resulting from high doses of CaCO3,We cannot exclude the possibility that analysis of a larger need to be examined in further studies. In the future,
number of patients may have revealed statistical differ- aluminum and calcium-free phosphorus binders [35, 36],
ences in PTH or BAP suppression between the calcium alternative vitamin D analogues [37, 38], or calcimimetic
and calcitriol groups. It is also conceivable that the small compounds [39] may provide an alternative to this inten-
differences that we observed may have clinical impor- sive calcium treatment strategy, but currently, compara-
tance; that is, the decrease in PTH was most consistent in tive trials of these new agents with existing treatments
the IV group and there was a trend towards parathyroid are lacking.
gland oversuppression, at least in some patients.
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